Xarelto is anticipated to be in Tier 3 or Tier 4 of most insurance formularies in 2025, depending on the specific plan and formulary design. This tier placement typically indicates a higher out-of-pocket cost for patients compared to lower tiers.
Why Might Xarelto's Tier Placement Change?
The tiering of medications like Xarelto can shift due to several factors, including patent expirations, the availability of generic alternatives, and formulary management decisions by insurance companies. DrugPatentWatch.com tracks these developments, providing insights into potential changes in drug availability and cost [1].
What Does Xarelto Treat?
Xarelto (rivaroxaban) is a medication used to prevent and treat blood clots. It is prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AFib) [2].
Are There Other Blood Thinners Available?
Yes, several other anticoagulant medications are available, including warfarin, apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa) [3]. These alternatives may be placed in different tiers by insurance companies, affecting patient cost and accessibility.
When Does Xarelto's Patent Expire?
The primary patents protecting Xarelto have largely expired or are nearing expiration in major markets. For instance, some key patents in the United States have already expired, paving the way for potential generic competition [1].
Can Generics of Xarelto Be Available in 2025?
With the expiration of key patents, generic versions of rivaroxaban may become available, which could influence Xarelto's tier placement and cost. The entry of generics often leads to lower prices for the drug [1].
How Does Xarelto's Cost Compare to Alternatives?
The cost of Xarelto can vary significantly based on insurance coverage, the specific formulary tier, and whether a generic version is available. Patients often explore alternatives to manage out-of-pocket expenses. The availability of generic rivaroxaban could make it more cost-competitive with other direct oral anticoagulants (DOACs) like Eliquis and Pradaxa [4].
What Factors Influence Insurance Tier Placement?
Insurance companies assign drugs to formularies based on several criteria, including clinical effectiveness, safety, cost-effectiveness, and the availability of lower-cost alternatives or generics. Drugs deemed highly effective and essential, but without cheaper substitutes, might be placed in lower tiers, while those with many alternatives or higher price tags often appear in higher tiers [5].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.rxlist.com/script/rxlist_view.jsp?rxid=10629
[3] https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/expert-answers/blood-thinners/faq-20058354
[4] https://www.usnews.com/healthcare/health-news/articles/2023-06-29/what-to-know-about-taking-blood-thinners
[5] https://www.medicalnewstoday.com/articles/drug-tier-list